Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Germany Decides On Added Benefit Of Gilead’s Veklury For COVID-19

Executive Summary

The body in charge of pricing and reimbursement in Germany has downgraded the extent of additional benefit offered by Gilead’s Veklury for treating COVID-19 patients.

You may also be interested in...



Confronting The Challenges Of Marketing Cell And Gene Therapies

The “chronic disease paradigm” presents a real challenge for companies marketing advanced therapies.

European Countries Call For Health Technology Assessments Of COVID-19 Products

Value assessments of COVID-19 monoclonal antibodies should inform pricing decisions, says cross country coalition.

CureVac Pulls Covid Vaccine From European Review Process

The company behind the CVnCOV COVID-19 vaccine candidate says the decision to withdraw from regulatory review is strategic. The EMA says outstanding issues affecting the benefit-risk balance remained to be answered at the time of withdrawal.

Topics

Related Companies

UsernamePublicRestriction

Register

PS145007

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel